丸美生物：“小金针超级面膜”有望成为下一核心增长点

Core Viewpoint - Marubi Biotechnology (603983) reported a revenue of 686 million yuan for Q3 2025, reflecting a year-on-year growth of 14.28%, and a net profit attributable to shareholders of 69 million yuan, up 11.59% year-on-year [1] Group 1 - The company launched a significant new product, the "Super Mask," in April this year, which is currently in a rapid growth phase [1] - Continuous marketing investment and consumer awareness building are expected to drive the sales of this product [1] - The "Super Mask" is anticipated to become a core growth driver in Q4 and next year, following the success of previous products like the "Little Red Pen" and "Little Gold Needle" [1]